Brand name: Zinbryta
Generic Name: daclizumab
Medication Class: humanized monoclonal antibody for MS
Similar Drugs: Other IL-2 antagonists include basiliximab (Simulect) used for kidney organ transplant rejection
Manufacturer: Biogen, AbbVie
Approval date: May 27, 2016
What is Zinbryta and its mechanism of action?
Zinbryta is an injectable medication used for the treatment of Multiple Sclerosis (MS). MS is one of the most common autoimmune diseases of the central nervous system (CNS). In MS, the body’s immune system attacks and damages nerves. White blood cells called T-cells are involved in the cellular damage that causes symptoms of MS. The T-cells enter the CNS through blood vessels and produce inflammation and secrete harmful chemicals. Zinbryta is an antibody. Although the exact mechanism of action of Zinbryta is unknown, scientists believe that it blocks the action of activated T-cells by binding to interleukin-2 (IL-2) receptors on the surface of T-cells. Binding to IL-2 receptors prevents IL-2 from activating T-cells which reduces damage to nerves and MS symptoms.
What is Zinbryta used for treating?
Zinbryta is used for treating patients with relapsing forms of Multiple Sclerosis (MS).
Zinbryta is reserved for patients who have had a poor response to two or more disease-modifying medications because it may cause liver injury and immune-mediated disorders.
MS is an autoimmune disorder of the CNS (brain, spinal cord, and optic nerves). In MS, the myelin sheaths (the fatty sheath that surrounds and protects nerve fibers) and oligodendrocytes (myelin-producing cells) in the CNS are damaged. Although the exact cause of MS in unknown, the body’s immune system, and T-cells are involved.
There are various types of MS. One type of MS is relapsing-remitting MS. People who have relapsing-remitting MS experience symptoms due to episodes of demyelination, and then improvement, usually getting symptoms again once every 6-18 months and improving again.
Next: Efficacy From Study Results, Side effects